The power of TOPMed imputation for the discovery of Latino enriched rare variants associated with type 2 diabetes

Competing Interest Statement

As of April 2022, P.D. is an employee and stockholder at Regeneron Pharmaceuticals. The rest of the authors declare no competing interests.

Funding Statement

Slim Initiative for Genomic Medicine in the Americas (SIGMA) was partially supported by a joint US-Mexico project funded by the Carlos Slim Health Institute. The UNAM/INCMNSZ Diabetes Study was supported by Consejo Nacional de Ciencia y Tecnologia grants 138826, 128877, SALUD 2009-01-115250, and a grant from Direccion General de Asuntos del Personal Academico, UNAM, IT 214711. The Mexico City Diabetes Study was supported by the National Heart, Lung and Blood Institute (ROHL24799), the Consejo Nacional de Ciencia y Tecnologia (grants 2099, M9303, F671-M9407, 251M, 2005-CO1-14502 and SALUD 2010-2-15-1165). SIGMA was also supported by funds from the Fundacion Carlos Slim (to J.C.F.). Resource for Genetic Epidemiology on Adult Heath and Aging (GERA) was supported by a grant (RC2 AG033067; PIs Schaefer and Risch) awarded to the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and the UCSF Institute for Human Genetics. The RPGEH was supported by grants from the Robert Wood Johnson Foundation, the Wayne and Gladys Valley Foundation, the Ellison Medical Foundation, Kaiser Permanente Northern California, and the Kaiser Permanente National and Northern California Community Benefit Programs. The Population Architecture Using Genomics and Epidemiology (PAGE) program is funded by the National Human Genome Research Institute (NHGRI) with co-funding from the National Institute on Minority Health and Health Disparities (NIMHD), supported by U01HG007416 (CALiCo), U01HG007417 (ISMMS), U01HG007397 (MEC), U01HG007376 (WHI), and U01HG007419 (Coordinating Center), R01HG010297, and R01HL151152. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The PAGE consortium thanks the staff and participants of the PAGE studies for their important contributions. The listing of PAGE senior investigators can be found at http://www.pagestudy.org. The data and materials included in this report result from collaboration between the following studies and organizations: The Hispanic Community Health Study/Study of Latinos was carried out as a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235), Northwestern University (N01-HC65236), and San Diego State University (N01-HC65237). The following Institutes/Centers/Offices contribute to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, NIH Institution-Office of Dietary Supplements. Samples and data of The Charles Bronfman Institute for Personalized Medicine (IPM) BioMe Biobank used in this study were provided by The Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai (New York). Phenotype data collection was supported by The Andrea and Charles Bronfman Philanthropies. Funding support for the Population Architecture Using Genomics and Epidemiology (PAGE) IPM BioMe Biobank study was provided through the National Human Genome Research Institute (U01 HG007417). The datasets used for the analyses described in this manuscript were obtained from dbGaP under accession phs000925. The Multiethnic Cohort study (MEC) characterization of epidemiological architecture is funded through the NHGRI Population Architecture Using Genomics and Epidemiology (PAGE) program (U01 HG007397). The MEC study is funded through the National Cancer Institute (R37CA54281, R01CA63, P01CA33619, U01CA136792, and U01CA98758). The datasets used for the analyses described in this manuscript were obtained from dbGaP under accession phs000220. Funding support for the Exonic variants and their relation to complex traits in minorities of the WHI study is provided through the NHGRI PAGE program (U01HG007376). The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. The datasets used for the analyses described in this manuscript were obtained from dbGaP under accession phs000227. Urban American Indians and Arizona Pima Indians cohorts. The Pima/Urban studies were supported by the intramural research program of NIDDK.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All human research approved was by the relevant Institutional Review Boards and conducted according to the Declaration of Helsinki. All participants provided written informed consent. For the Slim Initiative for Genomic Medicine in the Americas (SIGMA) Cohorts, all human research was approved by the Comité de ética e Investigación del Centro de Estudios en Diabetes, the Ethics and Research Committees of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, the Ethics and Research Committes of the Instituto Nacional de Medicina Genómica and the Federal Commission for the Protection against Health Risks (COFEPRIS) (CAS/OR/CMN/113300410D0027-0577/2012). The Mexican BioBank study involving human participants was reviewed and approved by the Research Ethics Committee (Approval CI-1479) of the National Institute of Public Health, Mexico). The Massachusetts General Biobank work was conducted with approval from the MGB Institutional Review Board (study 2016P001018).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes